Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

FOXA1 is a key determinant of estrogen receptor function and endocrine response.

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS.

Nat Genet. 2011 Jan;43(1):27-33. doi: 10.1038/ng.730. Epub 2010 Dec 12.

2.

More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.

Fu X, Huang C, Schiff R.

Breast Cancer Res. 2011 Apr 20;13(2):307. doi: 10.1186/bcr2849.

3.

Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.

Yamaguchi N, Nakayama Y, Yamaguchi N.

J Biol Chem. 2017 May 19;292(20):8136-8148. doi: 10.1074/jbc.M116.763276. Epub 2017 Mar 7.

4.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

5.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6.

6.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
7.

Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells.

Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, Catalano MG, Boccuzzi G.

Mol Cell Endocrinol. 2010 Jan 15;314(1):17-22. doi: 10.1016/j.mce.2009.09.011. Epub 2009 Sep 20.

PMID:
19772891
8.

Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Kong SL, Li G, Loh SL, Sung WK, Liu ET.

Mol Syst Biol. 2011 Aug 30;7:526. doi: 10.1038/msb.2011.59.

9.

Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells.

Holmes KA, Hurtado A, Brown GD, Launchbury R, Ross-Innes CS, Hadfield J, Odom DT, Carroll JS.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2748-53. doi: 10.1073/pnas.1018863108. Epub 2011 May 2.

10.

A co-ordinated interaction between CTCF and ER in breast cancer cells.

Ross-Innes CS, Brown GD, Carroll JS.

BMC Genomics. 2011 Dec 5;12:593. doi: 10.1186/1471-2164-12-593.

11.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

12.
13.

Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals.

Zhang XL, Wang HS, Liu N, Ge LC.

Arch Biochem Biophys. 2015 Nov 1;585:10-6. doi: 10.1016/j.abb.2015.09.006. Epub 2015 Sep 9.

PMID:
26363213
14.

FOXA1: a transcription factor with parallel functions in development and cancer.

Bernardo GM, Keri RA.

Biosci Rep. 2012 Apr 1;32(2):113-30. doi: 10.1042/BSR20110046. Review.

PMID:
22115363
15.

Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner.

Bretschneider N, Brand H, Miller N, Lowery AJ, Kerin MJ, Gannon F, Denger S.

Cancer Res. 2008 Jan 1;68(1):106-14. doi: 10.1158/0008-5472.CAN-07-5647.

16.

FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2.

Ahmed S, Al-Saigh S, Matthews J.

Mol Cancer Res. 2012 May;10(5):636-48. doi: 10.1158/1541-7786.MCR-11-0502.

17.

FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.

Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA.

Development. 2010 Jun;137(12):2045-54. doi: 10.1242/dev.043299.

18.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
19.

The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.

Wang C, Mayer JA, Mazumdar A, Brown PH.

Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.

20.

Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions.

Swinstead EE, Miranda TB, Paakinaho V, Baek S, Goldstein I, Hawkins M, Karpova TS, Ball D, Mazza D, Lavis LD, Grimm JB, Morisaki T, Grøntved L, Presman DM, Hager GL.

Cell. 2016 Apr 21;165(3):593-605. doi: 10.1016/j.cell.2016.02.067. Epub 2016 Apr 7.

Supplemental Content

Support Center